The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
METAPANC, intensified treatment in patients with oligometastatic pancreatic cancer: Multimodal surgical treatment versus systemic chemotherapy alone—A prospective randomized controlled multicenter phase III trial.
 
Peter Jo
No Relationships to Disclose
 
Michael Ghadimi
No Relationships to Disclose
 
Uwe Pelzer
No Relationships to Disclose
 
Marie-Theres Andrea Crede
No Relationships to Disclose
 
Ralph Telgmann
No Relationships to Disclose
 
Hanna Seppanen
No Relationships to Disclose
 
Svein Olav Bratlie
No Relationships to Disclose
 
Marc G. Besselink
Research Funding - Ethicon/Johnson & Johnson; Intuitive Surgical; Medtronic; Oncosil; Viatris; Viatris
 
Tim Friede
Consulting or Advisory Role - Actimed Therapeutics; ASLAN Pharmaceuticals; Bayer; CSL Behring; Daiichi Sankyo Europe GmbH; Enanta; Enanta; Fresenius Kabi; Galapagos NV; Johnson & Johnson; Mediconomics; Novartis; Roche/Genentech; VICO Therapeutics; Vifor Pharma
Speakers' Bureau - Fresenius Kabi
Research Funding - Abbott Vascular (Inst)
 
Jens T. Siveke
Leadership - Pharma15
Stock and Other Ownership Interests - Pharma15
Consulting or Advisory Role - AstraZeneca; AstraZeneca (Inst); Bayer; Bristol-Myers Squibb/Celgene; Falk Foundation; Immunocore; MCI Deutschland; MSD; MSD; Novartis; Roche; SERVIER
Research Funding - Abalos Therapeutics (Inst); Bristol-Myers Squibb (Inst); Eisbach Bio (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - SERVIER